John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
NEW YORK, Feb. 04, 2016 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, today announced management will be participating in the following investor conferences:
- Leerink 5th Annual Global Healthcare Conference on February 11, 2016 at 9:20 a.m. Eastern Time
- RBC Healthcare Conference on February 23, 2016 at 2:35 p.m. Eastern Time
Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases. The Company's lead product candidate, obeticholic acid (OCA), is an agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases, including primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. The FDA has granted OCA breakthrough therapy designation for the treatment of NASH with liver fibrosis and granted OCA fast track designation for the treatment of patients with PBC. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. Intercept's pipeline of product candidates includes other novel bile acid analogs such as INT-767, which is in clinical development. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
